Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Briefs: Appointments At Vision-Sciences, Positron, NanoString Technologies and Illuminoss Medical

This article was originally published in The Gray Sheet

Executive Summary

Vision-Sciences promotes interim chief to CEO and president. Positron names president. Medical device inventor and entrepreneur Thomas J. Fogarty joins SinuSys board. More people briefs.

You may also be interested in...



Financings In Brief

Molecular diagnostics firm AutoGenomics seeks to raise up to $65 million in an initial public offering. IlluminOss raises $28 mil. for fracture repair device. LoneStar Heart gets $20 million for heart failure implant. More financings.

Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel